Dossier assessment

Remdesivir (COVID-19) - Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A21-38
Last updated

Report documents

  1. Extract of dossier assessment

    Remdesivir (COVID-19) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 610 kB, EN, not accessible
  2. Dossier assessment

    Remdesivir (COVID-19) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 1 MB, DE, not accessible

Dossier assessment

Indication:

COVID-19 in adults and adolescents (aged 12 years and older with body weight at least 40 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)

Result of dossier assessment:

Adult patients with low-flow oxygen (LFO) at start of treatment: indication of considerable benefit.

Adolescent patients with low-flow oxygen (LFO) at start of treatment: added benefit not proven.

Patients with high-flow oxygen (HFO)/non-invasive ventilation (NIV) at start of treatment: added benefit not proven.

Press releases

Remdesivir in COVID-19: Indication of considerable added benefit for a part of the patients

COVID-19 patients with pneumonia who do not yet require high-flow oxygen therapy benefit from remdesivir: they recover more quickly and the risk of dying is reduced. These benefits are not proven for individuals with more severe disease.

Project details

Project no.
A21-38
Commission
Commission awarded on 01.04.2021 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Immune system and infections
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Connected Projects

  1. Dossier assessment

    Remdesivir (COVID-19, without supplemental oxygen, < 18 years of age) – Benefit assessment according to § 35a Social Code Book V

    Project no.
    A22-112
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Remdesivir (COVID-19) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A22-04
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form